Adaptive Biotechnologies empowers revolutionary insights into the adaptive immune system that will change the course of medicine.

Adaptive is at the forefront of immune-based discoveries, combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. We bring the accuracy and sensitivity of our immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care.

MISSION

Adaptive is committed to transforming the diagnosis and treatment of immune-mediated diseases including cancer, autoimmune disorders, and infectious disease through ground-breaking immunosequencing applications.

Adaptive Biotechnologies illuminates the adaptive immune system through high-throughput bias-controlled sequencing of T- and B-cell receptors, and makes this sequencing data accessible through a proprietary data analysis and visualization platform.

With constant dedication to discovery and ever-evolving product development, Adaptive empowers researchers and clinicians to discover the brilliance of the adaptive immune system.

Adaptive Biotechnologies is on the forefront of creating and enabling revolutionary immune-based discoveries that will radically advance science and medicine worldwide.

HISTORY

It was in a cafeteria at Fred Hutchinson Cancer Research Center in Seattle, where Dr. Harlan Robins, Dr. Chris Carlson and Dr. Edus Warren were collaborating on a research project. Over lunch one day, they started asking questions related to isolating and amplifying T-cell receptors from the human genome when they had an “aha!” moment.

Shortly after, in 2009, Adaptive Biotechnologies was born. The brain-child of two brothers (Chad and Harlan Robins) with one mission – to change the course of medicine and improve patient care worldwide. Over the years Adaptive has successfully gained the interest of strong investors, academic organizations and customers who understand the importance of sequencing the immune system in order to revolutionize the way we discover, diagnose and treat diseases.

To further the momentum, in 2015, Adaptive acquired Sequenta, Inc., a South San Francisco-based company dedicated to improving patient care in diseases mediated by immune cells through the discovery and development of novel clinical diagnostics.

Now with over 150 employees, two locations, and products and services in both the research and diagnostics segments, Adaptive is not just the pioneer but also the leader in immunosequencing that will change the course of medicine worldwide.

Chad Robins
President, Chief Executive Officer and Co-founder

Mr. Robins is our President, Chief Executive Officer and Co-founder. He has held executive level positions across multiple industries, including banking, real estate, investing and biotechnology. Prior to Adaptive, Mr. Robins was the Vice-President of Operations for Pulte Homes, and Chief Operating Officer for Connaught Real Estate Finance, an opportunistic hedge fund. He also opened the West Coast office of Wasserstein Perella’s software and internet services group then ran business development for HealthAxis.com, an online health insurance company. Mr. Robins was most recently recognized as one of Goldman Sachs “100 Most Intriguing Entrepreneurs,” and in 2012, Mr. Robins was a “40 Under 40” Seattle Leaders honoree. While in college and looking for a way to combine his adventuresome spirit with a vast learning opportunity, he spent 100 days in the wilderness with the National Outdoor Leadership School (NOLs) where he gained his open and interactive leadership style along with his strong teamwork mentality. A Cornell University honors graduate with a major in entrepreneurship and business, Mr. Robins obtained his MBA from The Wharton School at the University of Pennsylvania with a major in finance and concentrations in marketing and operations. In addition to the Adaptive Biotechnologies board, Mr. Robins holds board positions for the American Heart Association (Puget Sound) and Aortica Corporation.